1997
DOI: 10.1056/nejm199703203361203
|View full text |Cite
|
Sign up to set email alerts
|

Anaritide in Acute Tubular Necrosis

Abstract: The administration of anaritide did not improve the overall rate of dialysis-free survival in critically ill patients with acute tubular necrosis. However, anaritide may improve dialysis-free survival in patients with oliguria and may worsen it in patients without oliguria who have acute tubular necrosis.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
97
0
4

Year Published

1997
1997
2014
2014

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 404 publications
(101 citation statements)
references
References 18 publications
0
97
0
4
Order By: Relevance
“…[28][29][30][31] Although inhibition of p53 activation suppresses apoptosis, it may have no effect on primary necrosis. It should, however, reduce secondary necrosis, which is known to occur after apoptosis.…”
Section: Discussionmentioning
confidence: 99%
“…[28][29][30][31] Although inhibition of p53 activation suppresses apoptosis, it may have no effect on primary necrosis. It should, however, reduce secondary necrosis, which is known to occur after apoptosis.…”
Section: Discussionmentioning
confidence: 99%
“…Administration of ANP exerted beneficial effects in experimental and clinical acute renal failure [20,21]. We generated hypotensive transgenic mice overexpressing the mouse gene encoding BNP (Nppb) in the liver (BNP-Tg mice), which showed more than a 100-fold increase in plasma BNP and constitutive elevation of urinary guanosine 3′,5′-cyclic monophosphate (cGMP) levels [22].…”
mentioning
confidence: 99%
“…In conclusion, low-dose dopamine is not recommended for patients with CIN as it does not prevent the progression of kidney dysfunction. In a RCT of critically ill patients with AKI, including patients with CIN, the dialysis-free survival for 21 days after treatment, percentage of patients undergoing dialysis by day 14, and all-cause mortality by day 21 did not differ significantly between patients receiving high-dose hANP at 0.2 lg/kg/min for 24 h or those receiving placebo [186]. In a RCT of critically ill patients with oliguric AKI, the dialysisfree survival through day 21, percentage of patients undergoing dialysis by day 14, and mortality through day 60 did not differ significantly between patients receiving hANP and placebo [187].…”
Section: Level Of Evidence: I Grade Of Recommendation: D Rationale Cqmentioning
confidence: 93%